Unknown

Dataset Information

0

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.

ABSTRACT:

SUBMITTER: Niu X 

PROVIDER: S-EPMC4090260 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.

Niu X X   Wang G G   Wang Y Y   Caldwell J T JT   Edwards H H   Xie C C   Taub J W JW   Li C C   Lin H H   Ge Y Y  

Leukemia 20140217 7

Similar Datasets

Unknown MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
| S-EPMC4700051 | biostudies-literature
Genomics MLL-rearranged acute lymphoblastic leukemias upregulate BCL-2 through H3K79 methylation and are highly sensitive to the BCL-2 specific antagonist ABT-199
2015-12-17 | E-GEOD-74812 | biostudies-arrayexpress
Unknown Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.
| S-EPMC3975047 | biostudies-literature
Genomics MLL-rearranged acute lymphoblastic leukemias upregulate BCL-2 through H3K79 methylation and are highly sensitive to the BCL-2 specific antagonist ABT-199
2015-12-17 | GSE74812 | GEO
Unknown Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
| S-EPMC4154982 | biostudies-literature
Unknown Targeting MCL-1/BCL-XL Forestalls the Acquisition of Resistance to ABT-199 in Acute Myeloid Leukemia.
| S-EPMC4901329 | biostudies-literature
Unknown Integrated stress response activation induced by usnic acid alleviates BCL-2 inhibitor ABT-199 resistance in acute myeloid leukemia.
| S-EPMC12302291 | biostudies-literature
Unknown Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells.
| S-EPMC5085189 | biostudies-literature
Unknown ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
| S-EPMC4654800 | biostudies-literature
Unknown Targeting cytohesin-1 suppresses acute myeloid leukemia progression and overcomes resistance to ABT-199.
| S-EPMC10770340 | biostudies-literature